Generic Name and Formulations:
Antihemophilic Factor VIII (recombinant) 250 IU, 500 IU, 1000 IU; per bottle; lyophilized pwd for IV infusion after reconstitution; contains albumin; preservative-free.
Shire US, Inc.
Indications for RECOMBINATE:
Prevention and control of hemorrhagic episodes and perioperative management in Hemophilia A.
Adults and Children:
Dosage Required (IU) = Body Weight (kg) × Desired % Factor VIII Increase × 0.5. Infuse at rate of up to 10mL/min. Monitor pulse rate; if increased significantly, reduce infusion rate or hold. Hemorrhage: Mild: obtain 20–40% FVIII increase; give every 12–24hrs for 1–3 days until resolved. Moderate: obtain 30–60% FVIII increase; give every 12–24hrs for 3 days or until pain or disability resolved. Life-threatening: obtain 60–100% FVIII increase; give every 8–24hrs until resolved. Surgery: Minor: obtain 60–80% FVIII increase; give single infusion plus oral antifibrinolytic therapy within 1 hour; Major: pre- and post-op: obtain 80–100% FVIII increase; repeat every 8–24hrs based on healing.
Mouse, hamster, or bovine protein sensitivity.
Not for von Willebrand's disease. Confirm Factor VIII deficiency prior to treatment. Monitor for development of Factor VIII inhibitors. Latex allergy. Pregnancy (Cat.C).
Allergic reactions, nausea, fever, chills, urticaria, antibody formation.
Single-dose bottle—1 (w. diluent)
Clinical Pain Advisor Articles
- Opioid Use Disorders: Advances in Pharmacotherapy Provide Long-term Results
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- FDA Taps Social Media to Identify and Assess Emerging Drug Abuse Threats
- Buffered Lidocaine May Be Superior to Nonbuffered Lidocaine for Inferior Alveolar Nerve Block
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Marijuana's Uncertain Status: Closing the Gap Between State and Federal Policies